Eli Lilly Drug Reduces Risk of Diabetes Onset, Building Case for Broader Use of the Therapy
Posted
Frank Vinluan (via MedCity News)
In a Phase 3 study, Eli Lilly’s tirzepatide led to a 94% reduction in the risk that obese or overweight prediabetes patients progress to type 2 diabetes. Lilly was already planning to expand use of the blockbuster metabolic disorders drug to sleep apnea and heart failure.
The post Eli Lilly Drug Reduces Risk of Diabetes Onset, Building Case for Broader Use of the Therapy appeared first on MedCity News.
